345 N Reid Place, Suite 620, Sioux Falls, SD 57103. © American Consumer News, LLC dba ™ 2019-2023. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. It has collaboration agreements with HemoShear Therapeutics, LLC Alpine Immune Sciences, Inc. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use DUEXIS (ibuprofen/famotidine) tablets for oral use RAYOS (prednisone) delayed-release tablets for oral use and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion KRYSTEXXA (pegloticase injection) for intravenous infusion RAVICTI (glycerol phenylbutyrate) oral liquid PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use QUINSAIR (levofloxacin) solution for inhalation and UPLIZNA (inebilizumab-cdon) injection for intravenous use. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Grey received a Bachelor of Science in chemistry from the University of Nottingham in the United Kingdom. and Mirati Therapeutics Inc., both public biotechnology companies. Grey also serves on the boards of directors of BioMarin Pharmaceutical Inc. and Glaxo Holdings plc, culminating in his position as vice president, corporate development and director of international licensing. Before these, Grey served in various roles with Glaxo Inc. in 2001) and president of BioChem Therapeutic Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences Inc. He has 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals Inc. From February 2011 to June 2014, Grey served as president and chief executive officer of Lumena Pharmaceuticals Inc., a biotechnology company, which was acquired by Shire plc in June 2014. Grey served from October 2015 to January 2017 as the president and chief executive officer of Amplyx, from September 2014 to December 2017 as chairman and chief executive officer of Reneo and from May 2019 until April 2020 as executive chairman of Curzion Pharmaceuticals Inc., a private pharmaceutical company. He has also served as a venture partner at Pappas Ventures since January 2010. He has served as executive chairman of Spruce Biosciences Inc., a public biotechnology company, since April 2017 Amplyx Pharmaceuticals Inc., a private pharmaceutical company, since January 2017 Reneo Pharmaceuticals Inc., a private pharmaceutical company, since December 2017 and as chairman of Plexium Inc., a private biotechnology company, since August 2020. Before that he served as chief executive officer of Mirum from the company’s inception in March 2018. Grey has served as chairman of the board of directors of Mirum Pharmaceuticals Inc., a public biotechnology company, since January 2020, and as executive chairman from March 2019 to December 2019. Michael Grey has served on the board of directors since September 2011 and as lead independent director of the company since August 2012.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |